All In Biotech

Drug Trial Radar · NCT07943221

Study Evaluating Safety & Tolerability of Migaldendranib in US Healthy Volunteers

A Phase 1, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Migaldendranib (MGB) in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Oct 23, 2026

Study completion Nov 20, 2026

Sponsor

Lead sponsor
Ashvattha Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 24 healthy volunteers at 1 site in the United States.

Conditions

  • Healthy Volunteers

Interventions

  • Weekly subcutaneous administration of Migaldendranib (MGB)Drug

    Participants receive weekly subcutaneous administration of MGB

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: Varying timepoints through end of treatment, up to approximately 29 days per cohort.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medpace Clinical Pharmacology Unit

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.